A pharmaceutical study on controlling the release of a water soluble drug / Carol Yousry Ghattas ; Supervised Omaima N. Elgazayerly , Maha M. Amin
Material type: TextLanguage: English Publication details: Cairo : Carol Yousry Ghattas , 2018Description: 193 P. : charts , facsimiles ; 25cmOther title:- دراسة صيدلية على ضبط انطلاق عقار سريع الذوبان فى الماء [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.08.08.Ph.D.2018.Ca.P (Browse shelf(Opens below)) | Not for loan | 01010110076878000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.08.08.Ph.D.2018.Ca.P (Browse shelf(Opens below)) | 76878.CD | Not for loan | 01020110076878000 |
Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
The aim of the work in this thesis is to formulate controlled release VP-loaded multi-particulate systems with high encapsulation efficiency using either superhydrophobic or superamphiphobic substrates aiming to improve patient compliance by reducing its dosing frequency. To achieve this goal, the work in this thesis was divided into three chapters: Chapter I: Formulation and Evaluation of Verapamil-Loaded Chitosan and Chitosan/K-Carragenan Polyelectrolyte Complex Spherical Hydrogel Beads using Superhydrophobic Substrates. Chapter II: Formulation and Evaluation of Verapamil-Loaded Polymeric Spherical Beads using Superamphiphobic Substrates. Chapter III: In vivo Performance of the Optimized Verapamil-Loaded Beads. From these chapters, it could be concluded that superhydrophobic and superamphiphobic substrates could be applied in formulating controlled release multi-particulate systems with high encapsulation efficiency of water soluble drug as Verapamil. Also, it could be concluded that the two optimized formulated systems (F8/3.58- capsule and S18/19-capsule) achieved prolonged in vivo residence as they showed 2.2 and 2.7 folds increment in the mean residence time as well as 5.24 and 3.93 times in vivo retardation respectively relative to the market product (Isoptin®). Hence, they could allow once daily administration instead of three times per day in case of Isoptin® which might result in higher patient compliance
Issued also as CD
There are no comments on this title.